Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 5/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19814711 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL8149970 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL1097570 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL858969 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14946298 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14853815 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL19258430 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL2767589 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL7128636 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL5696111 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340488-A1 | TREATMENT OF SKIN DISEASES AND DISORDERS USING INHIBITORS OF KALLIKREIN-RELATED PEPTIDASES (KLK) | EXICURE OPERATING COMPANY (US) | 2023-10-26 | — | — | US | claimed |
| EP-4192477-A1 | TREATMENT OF SKIN DISEASES AND DISORDERS USING INHIBITORS OF KALLIKREIN-RELATED PEPTIDASES (KLK) | Exicure Operating Company (US) | 2023-06-14 | — | — | EP | claimed |
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | claimed |
| EP-1015469-B1 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2005-04-13 | — | — | EP | claimed |
| CN-122031506-A | Chiral control | 波涛生命科学有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12583883-B2 | Asymmetric auxiliary group | WAVE LIFE SCIENCES LTD. (SG) | 2026-03-24 | — | — | US | disclosed |
| EP-4577650-A1 | CHEMICAL MODIFICATION OF GUIDE RNAS WITH LOCKED NUCLEIC ACID FOR RNA GUIDED NUCLEASE-MEDIATED GENE EDITING | Life Edit Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250188477-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| EP-4495241-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-6639059-B1 | Novel synthesis strategy comprising novel key intermediate, (2.2.1)bicyclo nucleosides are produced at least two steps shorter than any previously known strategy; 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-alpha-D-ribofuranose | EXIQON A/S (DK) | 2003-10-28 | — | — | US | disclosed |
| US-20030144231-A1 | Oligonucleotide analogues | EXIQON A/S (DK) | 2003-07-31 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
| US-20030105309-A1 | Novel bicyclonucleoside and oligonucleotide analogue | TAKESHI IMANISHI (JP) | 2003-06-05 | — | — | US | disclosed |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | EXIQON A/S | 2003-05-15 | — | — | US | disclosed |
| US-20020068708-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2002-06-06 | — | — | US | disclosed |
| US-6268490-B1 | NUCLEOSIDE ANALOG; FOR ANTISENSE AGENT WHICH IS HYDROLASE RESISTANT, HAS HIGH SENSE STRAND BINDING ABILITY AND IS EASILY SYNTHESIZED | TAKESHI IMANISHI (JP) | 2001-07-31 | — | — | US | disclosed |
| EP-1013661-A1 | NOVEL BICYCLONUCLEOSIDE AND OLIGONUCLEOTIDE ANALOGUES | Imanishi, Takeshi (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068708-A1 | OLIGONUCLEOTIDE ANALOGUES | DCLRE1B, TARBP1, NCL | TK1 9/4885ALDH1A1 3261/4885LMNA 291/4885 |
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | TK1 7/4885ALDH1A1 3403/4885LMNA 271/4885 |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | TFRC, FOLR2, FTH1 | TK1 1338/4885ALDH1A1 4456/4885LMNA 4287/4885 |
| US-12583883-B2 | Asymmetric auxiliary group | AGL, RNMT, NSUN2 | TK1 260/4885ALDH1A1 1865/4885LMNA 1824/4885 |
| US-20030144231-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | TK1 7/4885ALDH1A1 3403/4885LMNA 271/4885 |
| US-20030105309-A1 | Novel bicyclonucleoside and oligonucleotide analogue | DCLRE1B, POLA1, POLB | TK1 16/4885ALDH1A1 1559/4885LMNA 2272/4885 |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | NSUN2, RNGTT, RNMT | TK1 72/4885ALDH1A1 617/4885LMNA 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.